ABSTRACT
Effect of immunomodulators for microbial origin on innate immunity and antitumor system was continued to study. Immunomodificator Immunovac VP-4, purified staphylococcal toxoid and glucosaminyl muramyl dipeptide (GMDP) equally enhanced cytotoxicity of mononuclear leukocytes of peripheral blood of healthy donors. Index of cytotoxicity was 2.78, 2.77 and 2.70 respectively. Reduced metastatic progression of Lewis lung carcinoma in mice was observed after Immunovac VP-4 and GMDP administration. Effectiveness was seen when preparations administered according to schedules including their administration before implantation of the tumor. If preparations were administered number of metastases reduced in 4.4-5.6 times and size of metastases reduced in 7-10 times. Interplay between antitumor activity of studied immunomodulators and cytotoxic activity of NK-cells, which are base effectors of antitumor immune response, are discussed.
Subject(s)
Acetylmuramyl-Alanyl-Isoglutamine/analogs & derivatives , Adjuvants, Immunologic/therapeutic use , Bacterial Vaccines/immunology , Bacterial Vaccines/therapeutic use , Carcinoma, Lewis Lung/drug therapy , Immunologic Factors/immunology , Leukocytes, Mononuclear/immunology , Lung Neoplasms/drug therapy , Staphylococcal Toxoid/immunology , Staphylococcal Toxoid/therapeutic use , Vaccines, Combined/immunology , Vaccines, Combined/therapeutic use , Acetylmuramyl-Alanyl-Isoglutamine/immunology , Acetylmuramyl-Alanyl-Isoglutamine/therapeutic use , Adjuvants, Immunologic/administration & dosage , Animals , Bacterial Vaccines/administration & dosage , Carcinoma, Lewis Lung/pathology , Carcinoma, Lewis Lung/secondary , Cytotoxicity Tests, Immunologic , Drug Administration Schedule , Humans , Injections, Intraperitoneal , K562 Cells , Lung/pathology , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Mice , Mice, Inbred C57BL , Neoplasm Metastasis/drug therapy , Staphylococcal Toxoid/administration & dosage , Vaccines, Combined/administration & dosageABSTRACT
Chronic experiments lasting for 5 weeks were carried out in 40 nonpedigree mature dogs. It has been detected that preliminary immunization with staphylococcus anatoxin potentiates the compensation mechanisms in the course of postresuscitation period, stimulates cell proliferation by increasing cardiac output that is an adaptive reaction of the cardiovascular system in postresuscitation period and provides optimal metabolism of the organism.
Subject(s)
Cardiac Output/drug effects , Immunization , Resuscitation , Staphylococcal Toxoid/therapeutic use , Animals , Cell Proliferation/drug effects , Dogs , Myocardium/pathology , Shock, Hemorrhagic/therapy , Staphylococcal Toxoid/administration & dosageABSTRACT
32 patients with atopic dermatitis (AD), complicated by pyoderma, were treated with purified staphylococcal toxoid (PST). Changes in clinical and laboratory characteristics in the course of treatment were evaluated. PST was shown to produce a satisfactory therapeutic effect, arresting the symptoms of local staphylococcal infection. An increase in the levels of alpha- and gamma-interferons and decreased content of CD25+ lymphocytes were found. Thus prospects appear for using this preparation as an interferon inductor, as well a for the immunotherapy of AD patients sensitized to Staphylococcus aureus.
Subject(s)
Dermatitis, Atopic/therapy , Interferon Inducers/therapeutic use , Staphylococcal Toxoid/therapeutic use , Adolescent , Adult , Child , Dermatitis, Atopic/complications , Dermatitis, Atopic/immunology , Humans , Interferon-alpha/blood , Interferon-gamma/blood , Lymphocyte Count , Lymphocytes/immunology , Pyoderma/complications , Receptors, Interleukin-2/analysis , Staphylococcal Infections/etiologySubject(s)
Acetylmuramyl-Alanyl-Isoglutamine/analogs & derivatives , Adjuvants, Immunologic/therapeutic use , Immunologic Deficiency Syndromes/drug therapy , Staphylococcal Toxoid/therapeutic use , Acetylmuramyl-Alanyl-Isoglutamine/therapeutic use , Animals , Antibody Formation/drug effects , Bacterial Vaccines/therapeutic use , Drug Therapy, Combination , Humans , Immune Tolerance/drug effects , Immunologic Deficiency Syndromes/immunology , Viral Vaccines/therapeutic useABSTRACT
The aim of the work done was to improve treatment options for focal Staphylococcus-induced diseases in adolescents and children with the aid of adsorbed staphylococcal anatoxin (ASA) concurrently with low-intensive EHF therapy. Overall fifty patients aged 3 to 17 years with Staphylococcus infection in tonsils, nose, ears were kept under medical surveillance. ASA and EHF therapies were instituted according to the developed schemes of such therapies. Positive dynamics was shown of clinical picture and parameters characterizing humoral and cell-mediated immunity. There were no unfavourable side-effects. The proposed mode of treatment can, we believe, be widely used in a clinical setting.
Subject(s)
Focal Infection/immunology , Focal Infection/therapy , Staphylococcal Infections/immunology , Staphylococcal Infections/therapy , Adolescent , Adsorption , Antibody Formation/drug effects , Antibody Formation/radiation effects , Child , Child, Preschool , Combined Modality Therapy , Female , Humans , Immunity, Cellular/drug effects , Immunity, Cellular/radiation effects , Male , Microwaves/therapeutic use , Staphylococcal Toxoid/therapeutic useABSTRACT
The action of information stress for 14 days leads to the development of immunosuppression, which is manifested by the suppression of humoral response to sheep red blood cells (SRBC) and the decrease of resistance to Langat virus having low pathogenicity. As shown in this investigation, an immunomodifier, purified staphylococcal toxoid (PST), protects experimental animals from the immunosuppressive effect of information stress. After the injection of PST to stress-affected mice in doses of 15 or 1.5 binding units per animal on days 9, 11 and 13 of the experiment their humoral response to SRBC and resistance to Langat virus are partially restored (by 45-60%).
Subject(s)
Adjuvants, Immunologic/therapeutic use , Immune Tolerance/drug effects , Staphylococcal Toxoid/therapeutic use , Stress, Psychological/immunology , Animals , Animals, Suckling , Antibody Formation/drug effects , Disease Models, Animal , Drug Evaluation, Preclinical , Encephalitis Viruses, Tick-Borne , Encephalitis, Tick-Borne/drug therapy , Encephalitis, Tick-Borne/etiology , Encephalitis, Tick-Borne/immunology , Immune Tolerance/immunology , Male , Mice , Mice, Inbred BALB C , Serial Passage , Stress, Psychological/complications , Stress, Psychological/drug therapy , Time FactorsSubject(s)
Adjuvants, Immunologic/therapeutic use , Coxsackievirus Infections/prevention & control , Enterovirus B, Human , Pertussis Vaccine/therapeutic use , Staphylococcal Toxoid/therapeutic use , Animals , Coxsackievirus Infections/mortality , Drug Evaluation, Preclinical , Mice , Mice, Inbred BALB C , Time Factors , Vaccines, Combined/therapeutic useSubject(s)
Adjuvants, Immunologic/therapeutic use , Coxsackievirus Infections/drug therapy , Enterovirus B, Human , Immunologic Deficiency Syndromes/drug therapy , Staphylococcal Toxoid/therapeutic use , Animals , Coxsackievirus Infections/complications , Drug Evaluation, Preclinical , Immunologic Deficiency Syndromes/etiology , Mice , Mice, Inbred BALB C , Time FactorsABSTRACT
Inbred mice have proved to be a promising model for the evaluation of antigen-specific and antigen-nonspecific immunomodulating activity of purified staphylococcal toxoid in humans. This toxoid induces the formation of pronounced humoral response to homologous and heterologous infections in humans and mice. In animal experiments purified staphylococcal toxoid has shown its capacity for the correction of secondary immune deficiency of different origin; when introduced into humans having secondary immunodeficiency associated with bacterial infections of different etiology, the preparation reproduces this effect.
Subject(s)
Immunotherapy/methods , Staphylococcal Toxoid/therapeutic use , Acute Disease , Animals , Antibody Formation , Disease Models, Animal , Drug Evaluation , Drug Evaluation, Preclinical , Female , Humans , Immunity, Cellular , Mice , Mice, Inbred BALB C , Mice, Inbred CBA , Pelvic Inflammatory Disease/therapy , Staphylococcal Infections/immunology , Staphylococcal Infections/therapy , Staphylococcal Toxoid/isolation & purificationABSTRACT
Purified staphylococcal toxoid is capable of partially preventing the development of antigen-specific (induced by the supraoptimal dose of sheep red blood cells) and antigen-nonspecific (induced by Tahyna virus) defects of humoral immune response, as well as abolishing these defects. The presence and manifestation of the correction of virus-induced immunodeficiency is determined by the dose of the toxoid and the interval between the injections of purified staphylococcal toxoid and the infective agent.
Subject(s)
Encephalitis Virus, California , Encephalitis, California/therapy , Epitopes/drug effects , Immune System Diseases/therapy , Staphylococcal Toxoid/therapeutic use , Animals , Antibody Formation/drug effects , Antibody Formation/immunology , Dose-Response Relationship, Immunologic , Drug Evaluation, Preclinical , Encephalitis, California/etiology , Encephalitis, California/immunology , Epitopes/immunology , Immune System Diseases/etiology , Immune System Diseases/immunology , Immunization/methods , Mice , Mice, Inbred CBA , Staphylococcal Toxoid/isolation & purification , Time FactorsSubject(s)
Amputation, Traumatic/therapy , Bacterial Vaccines/therapeutic use , Fractures, Open/therapy , Proteus/immunology , Staphylococcal Toxoid/therapeutic use , Wound Infection/prevention & control , Adolescent , Adult , Amputation, Traumatic/complications , Amputation, Traumatic/immunology , Combined Modality Therapy , Drug Evaluation , Female , Fractures, Open/complications , Fractures, Open/immunology , Humans , Immunization/methods , Male , Middle Aged , Wound Infection/immunologySubject(s)
Cicatrix/complications , Esophageal Stenosis/therapy , Laryngostenosis/therapy , Staphylococcal Toxoid/therapeutic use , Tracheal Stenosis/therapy , Adult , Chronic Disease , Esophageal Stenosis/etiology , Female , Humans , Laryngostenosis/etiology , Male , Middle Aged , Tracheal Stenosis/etiologyABSTRACT
An analysis of clinico-immunological data has demonstrated a considerable decline in non-specific and specific defences against such major factors of hospital infection in esophageal cancer patients as staphylococcal, blue pus and Proteus bacilli. Immunization with a complex vaccine including concentrated staphylococcal anatoxin, blue pus and Proteus vaccines was shown to stimulate the said factors of anti-infectious immunity and to be followed by a 4.7-fold decrease in the incidence of postoperative pyo-inflammatory complications. The said vaccine may be recommended for prevention of infectious complications in cancer patients since its administration is followed by a low-level reaction matched by a marked increase in immunologic vigor.